Argenx
ARGX
#496
Rank
A$70.21 B
Marketcap
A$1,123
Share price
-0.14%
Change (1 day)
27.63%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$21.87. In 2024 the company made an earnings per share (EPS) of A$19.26 an increase over its 2023 EPS that were of A-$7.14.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66
2024A$19.26-369.77%
2023A-$7.14-60.46%
2022A-$18.0563.33%
2021A-$11.05-40.37%
2020A-$18.54183.47%
2019A-$6.54123.09%
2018A-$2.9354.93%
2017A-$1.8914.07%
2016A-$1.6613.05%
2015A-$1.47-36.34%
2014A-$2.30209.04%
2013A-$0.75-33.99%
2012A-$1.13185.59%
2011A-$0.40